Zoetis (0M3Q) AI Stock Analysis

Zoetis

(LSE:0M3Q)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong profitability and cash generationHigh margins and substantial cash generation indicate a resilient, asset-light earnings model with strong conversion from profit to cash. This provides Zoetis with funding for research, product launches, acquisitions, dividends, and share repurchases while supporting durability through market cycles.

Negative Factors

Lowered 2026 outlookThe reduced outlook signals that current operating pressure is material enough to affect full-year earnings, not merely quarterly results. Declining revenue and profit guidance can constrain near-term reinvestment capacity and indicate that recovery in core franchises may take time.

Zoetis (0M3Q) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: $32.94B
Dividend Yield: 2.66%
Average Volume (3M): 13.46K
Price to Earnings (P/E): 13.1
Beta (1Y): 1.17
Revenue Growth: 1.41%
EPS Growth: 4.54%
Country: UK
Employees: 14,500
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Zoetis Business Overview & Revenue Model

Company Description

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of...

Zoetis Earnings Call Summary

Earnings Call Date:Aug 05, 2026(Q2-2026)|% Change Since:12.35%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentNegative

The call presented a mixed picture: clear strengths in Livestock, Diagnostics, international and continued pipeline progress, plus disciplined cost and capital return actions. However, material weakness in core Companion Animal markets—especially U.S. Dermatology and parasiticides—intensified competitive promotional activity, declining clinic visits, price realization pressure from gross-to-net investments, generics, and a meaningful downward revision to full-year guidance. While the portfolio diversification and cost actions provide resilience, the near-term trends in the company’s largest franchise create significant headwinds.

Positive Updates

Strong Livestock Performance

Livestock revenue grew 11% in Q2 to $731 million (U.S. Livestock up 23% to $222 million), driven by cattle and poultry demand, vaccine wins, hatchery programs, and elevated demand (e.g., New World screwworm response). Management expects mid- to high-single-digit sustainable growth for the business on a normalized basis.

Negative Updates

Companion Animal Revenue Weakness

Global Companion Animal revenue declined 6% in Q2 to $1.7 billion; U.S. Companion Animal was down 11% to $1.0 billion. Core Dermatology (Key Dermatology) declined 16% to $395 million and U.S. Dermatology declined 18% to $251 million, reflecting softer clinic visits and intensified competition.

Company Guidance

Zoetis updated full‑year 2026 guidance to revenue of $9.12–9.32 billion (organic operational growth -3% to -1% year‑over‑year), adjusted net income of $2.57–2.62 billion (organic operational decline -9% to -5% Y/Y), adjusted diluted EPS of $6.15–6.25 and reported diluted EPS of $5.55–5.65. The outlook reflects Q2 results (Q2 revenue $2.5 billion, flat reported and -1% organic; adjusted net income $781 million, -2% organic), continued U.S. Companion Animal pressure offset by strength in Livestock and Diagnostics, and assumes late‑July FX rates (approximately $60–65 million adverse to revenue and ~$30 million to the bottom line). Guidance also embeds the company’s planned gross‑to‑net investments (Wetteny noted price realization for the year could be roughly 0% to -1%, potentially as much as -2% at the low end), and reflects current margin and cost actions (adjusted gross margin 72.9%, ~40 bps reported decline with ~50 bps FX headwind and ~10 bps ex‑FX expansion; adjusted operating expenses $764 million, SG&A $586 million down ~4% operationally, R&D $173 million up ~4% operationally).

Zoetis Risk Analysis

Zoetis disclosed 51 risk factors in its most recent earnings report. Zoetis reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Zoetis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0M3Q against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PAHC	73Outperform	$1.58B	15.80	28.67%	1.23%	17.12%	106.40%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ELAN	53Neutral	$11.52B	-56.24	-3.02%	―	11.95%	-145.71%

* General Sector Average

Performance Comparison

GB:0M3Q and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0M3Q	Zoetis	79.65	-61.61	-43.62%
PAHC	Phibro Animal Health Corp	38.88	-3.96	-9.24%
ELAN	Elanco Animal Health	23.06	0.21	0.92%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Zoetis AI Stock Analysis